期刊
LANCET
卷 378, 期 9786, 页码 156-167出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)60698-3
关键词
-
资金
- National Health Service Denmark
- Danish Council for Strategic Research
- Danish Research Foundation for General Practice
- Danish Centre for Evaluation and Health Technology Assessment
- Danish National Board of Health
- Danish Medical Research Council
- Aarhus University Research Foundation
- Wellcome Trust [G061895]
- UK Medical Research Council
- UK NIHR
- UK National Health Service RD
- Julius Center for Health Sciences and Primary Care
- University Medical Center
- Utrecht
- Novo Nordisk
- Astra
- Pfizer
- GlaxoSmithKline
- Servier
- HemoCue
- Merck
- National Health Services, Copenhagen, Denmark
- National Health Services, Aarhus, Denmark
- National Health Services, Ringkobing, Denmark
- National Health Services, Ribe, Denmark
- National Health Services, South Jutland, Denmark
- Novo Nordisk Foundation
- National Board of Health
- Novo Nordisk AS
- Novo Nordisk Scandinavia AB
- Novo Nordisk UK
- ASTRA Denmark
- Pfizer Denmark
- GlaxoSmithKline Pharma Denmark
- Servier Denmark
- HemoCue Denmark
- Medical Research Council [G0001164]
- NIHR [08/116/300, RP-PG-0606-1259]
- National Health Service
- Department of Health [RP-PG-0606-1272]
- ad hoc Support Sciences
- Medical Research Council [G0001164, MC_U106179471, G0501294, MC_U106179474] Funding Source: researchfish
- National Institute for Health Research [RP-PG-0606-1259, 08/116/300] Funding Source: researchfish
- MRC [MC_U106179474, G0001164, G0501294] Funding Source: UKRI
Background Intensive treatment of multiple cardiovascular risk factors can halve mortality among people with established type 2 diabetes. We investigated the effect of early multifactorial treatment after diagnosis by screening. Methods In a pragmatic, cluster-randomised, parallel-group trial done in Denmark, the Netherlands, and the UK, 343 general practices were randomly assigned screening of registered patients aged 40-69 years without known diabetes followed by routine care of diabetes or screening followed by intensive treatment of multiple risk factors. The primary endpoint was first cardiovascular event, including cardiovascular mortality and morbidity, revascularisation, and non-traumatic amputation within 5 years. Patients and staff assessing outcomes were unaware of the practice's study group assignment. Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00237549. Findings Primary endpoint data were available for 3055 (99.9%) of 3057 screen-detected patients. The mean age was 60.3 (SD 6.9) years and the mean duration of follow-up was 5.3 (SD 1.6) years. Improvements in cardiovascular risk factors (HbA(1c) and cholesterol concentrations and blood pressure) were slightly but significantly better in the intensive treatment group. The incidence of first cardiovascular event was 7.2% (13.5 per 1000 person-years) in the intensive treatment group and 8.5% (15.9 per 1000 person-years) in the routine care group (hazard ratio 0.83, 95% CI 0.65-1.05), and of all-cause mortality 6.2% (11.6 per 1000 person-years) and 6.7% (12.5 per 1000 person-years; 0.91, 0.69-1.21), respectively. Interpretation An intervention to promote early intensive management of patients with type 2 diabetes was associated with a small, non-significant reduction in the incidence of cardiovascular events and death.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据